REFINED ALKALI TREATMENT OF NEPHROLITHIASIS

本项目的总体目标是确定（a）一个特殊的 正磷酸盐制剂（缓释磷酸钾或UroPhos-K） 会产生生理-物理化学纠正，抑制结石 形成，并提供吸收性高钙尿症的使用安全性，以及 (b)新型柠檬酸盐制剂（柠檬酸钾镁或K-Mag） 将抑制结石形成，并为患有以下疾病的患者提供使用安全性 钙结石 在目标1中，我们将检查UroPhos-K对 结石形成盐的结晶，而病人保持在一个 恒定代谢饮食。目标2，对满意的完成进行表扬 目标1，将是UroPhos-K和 安慰剂对结石形成的影响。在目标3中，我们将继续进行随机化 K-Mag和安慰剂对结石形成的试验。最后，Aim 4将 评估钾镁在预防低钾血症和镁的价值 服用噻嗪类药物治疗高尿钙性肾结石的患者中的消耗。 这个项目在生物医学上很重要，因为它可能导致 开发UroPhos-K作为一种合理有效的治疗 吸收性高钙尿症，以及K-Mag作为优于钾的药物 柠檬酸盐。

The overall goals of this project are to determine whether (a) a special orthophosphate preparation (slow-release potassium phosphate or UroPhos-K) would produce physiological-physicochemical correction, inhibit stone formation, and provide safety of usage in absorptive hypercalciuria, and (b) a novel citrate formulation (potassium-magnesium citrate or K-Mag) would inhibit stone formation and provide safety of usage in patients with calcium stones. In Aim 1, we shall examine the effect of UroPhos-K on the crystallization of stone-forming salts while patients are kept on a constant metabolic diet. Aim 2, to commense upon satisfactory completion of Aim 1, will be a long-term randomized trial between UroPhos-K and placebo on stone formation. In Aim 3, we shall continue ongoing randomized trial between K-Mag and placebo on stone formation. Finally, Aim 4 will assess the value of K-Mag in preventing hypokalemia and magnesium depletion in patients taking thiazide for hypercalciuric nephrolithiasis. This project is biomedically important, since it could lead to the development of UroPhos-K as a rational and effective treatment of absorptive hypercalciuria, and of K-Mag as a superior drug over potassium citrate.